NextCure Inc (NASDAQ:NXTC) has been given a consensus broker rating score of 1.17 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and two have assigned a strong buy rating to the company.
Brokerages have set a 12 month consensus price objective of $25.33 for the company and are anticipating that the company will post ($0.47) earnings per share for the current quarter, according to Zacks. Zacks has also assigned NextCure an industry rank of 69 out of 256 based on the ratings given to its competitors.
A number of equities analysts recently weighed in on NXTC shares. Piper Jaffray Companies lowered shares of Cypress Semiconductor from an “overweight” rating to a “neutral” rating in a research report on Monday, June 3rd. Bank of America reiterated a “buy” rating and issued a $43.00 price objective (up from $36.00) on shares of The Medicines in a research report on Tuesday, July 9th. Finally, Morgan Stanley lowered shares of Meili from an “equal weight” rating to an “underweight” rating and lowered their price objective for the company from $14.00 to $4.20 in a research report on Monday, June 3rd.
In related news, Director Stella Xu bought 125,000 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $1,875,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder X L.P. Canaan bought 50,000 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were bought at an average price of $15.00 per share, for a total transaction of $750,000.00. The disclosure for this purchase can be found here.
NASDAQ:NXTC traded down $0.29 during midday trading on Tuesday, reaching $16.28. The stock had a trading volume of 26,058 shares, compared to its average volume of 81,624. The business’s fifty day simple moving average is $16.31. NextCure has a 12-month low of $13.86 and a 12-month high of $22.75.
NextCure (NASDAQ:NXTC) last posted its quarterly earnings data on Monday, June 10th. The company reported ($4.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($3.93). The company had revenue of $1.36 million for the quarter. As a group, equities research analysts anticipate that NextCure will post -2.08 earnings per share for the current year.
NextCure Company Profile
There is no company description available for NextCure Inc
Featured Article: Hold Rating
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.